

## North of Tyne, Gateshead and North Cumbria Area Prescribing Committee

## **Apomorphine Shared Care Guidance**

For the Management of Advanced Parkinson's Disease.

Introduction	Indication: Dopamine agonist used for the treatment of motor fluctuations in patients with advanced Parkinson's disease not sufficiently controlled by oral anti-Parkinson medication. Apomorphine is given as a continuous subcutaneous infusion over 12 hours, or via intermittent injection for treatment at the onset of an off period.  This shared care agreement covers the administration of intermittent subcutaneous injections using the pre-filled pens. Using the Apo-go brand as per the North of Tyne Formulary.  Dose: Patient specific and calculated based on apomorphine challenge; this will be confirmed in specialist correspondence.  Doses do not normally exceed 4mg/hour.				
Specialist Responsibilities	<ul> <li>Initial assessment and prescribing:</li> <li>Initiate and supply medication for first three months as a minimum or until the dose is stabilised.</li> <li>Domperidone pre-loading to manage associated nausea and subsequent withdrawal.</li> <li>Patient and carer counselling.</li> <li>Initial safety monitoring: <ul> <li>FBC</li> <li>Reticulocyte count</li> <li>Direct antiglobulin test (Coombs test) – Available on ICE</li> <li>ECG</li> </ul> </li> <li>Ongoing Responsibilities: <ul> <li>Assess and monitor patients' response to treatment and the need to continue therapy on at least a 12 monthly basis.</li> <li>Provide the GP with relevant information for each patient including treatment plan</li> <li>Report any suspected ADRs to CSM via Yellow Card system.</li> </ul> </li> </ul>				
	Provide GP with any further advice if required				
GP Responsibilities	Maintenance prescribing:  Prescribe apomorphine as directed by hospital correspondence:  Intermittent subcutaneous injection: defined dose at time of transfer of care.				
	Physical Monitoring: FBC, reticulocyte count and Direct antiglobulin test (Coombs test) every 6 months (all available via ICE)				
	<ul> <li>Further Responsibilities:</li> <li>Report any adverse effects to specialist and regulatory bodies i.e. CSM via Yellow Card process</li> <li>Liaise with consultant regarding any complications of treatment</li> <li>Ask the specialist to take back the prescribing should unmanageable problems arise</li> </ul>				
Approval Date: 10/2020	Review Date: 10/2023 1				



	<ul> <li>Provision of 1L sharps bins</li> <li>Supply of Needles- compatible with insulin pen needles, no longer than 12mm and not finer than 0.33mm (29G)</li> <li>GlucoRx or BD viva needles should be prescribed in line with local arrangements at a cost of less than £5 per 100 needles.</li> </ul>						
	Contraindications:      Pregnancy or breastfeeding     Respiratory or CNS depression     Hepatic impairment     Dementia     Neuropsychiatric conditions     History of hypersensitivity to opioids Cautions:     Cardiovascular disease     Susceptibility to QT-interval prolongation     Pulmonary disease     History of postural hypotension Adverse Effects						
	Adverse Effect	Action					
Adverse Effects, Precautions,	Nausea , vomiting – more common on initiation	Manage with Domperidone 10 mg 3 times per day, if not contra-indicated following ECG (specialist as above)					
Contraindications	Clinical Deterioration( motor, confusion, hallucinations, psychosis)	Contact consultant or movement disorder nurse specialist					
	Injection site nodules	Ensure injection site rotation & Contact movement disorder nurse specialist					
	Abnormal FBC (thrombocytopenia)	Contact consultant or movement disorder nurse specialist					
	Haemolysis and/or +ve Direct antiglobulin test (Coombs test)	Contact consultant or movement disorder nurse specialist					
	Impulse control disorders	Contact consultant or movement disorder nurse specialist					
	As with all other anti- Parkinson's medications and secondary to disease progression patients will be at risk of hypotension and drowsiness.						
	Antiparkinsonian treatments should never be stopped suddenly as this carries a small risk of neuroleptic malignant syndrome.						
Common Drug Interactions	<ul> <li>Alcohol- increased risk of drowsiness</li> <li>Ondansetron- increased risk hypotension</li> <li>Nitrates, Calcium-channel blockers, and Alpha blockers- The hypotensive adverse effects of apomorphine might possibly be increased.</li> <li>The concurrent use of more than one drug that prolongs the QT interval increases the risk of torsade de pointes, which might lead to</li> </ul>						
Communication/Contact Details	life-threatening ventricular arrhythmias.  Named Specialist Mon – Fri 09:00 – 17:00  Gateshead QE via switchboard: 0191 482 0000  Newcastle Upon Tyne Hospitals via 0191 233 6161  Northumbria Healthcare NHS foundation Trust via 0344 811 8111						

This information is not inclusive of all prescribing information and potential adverse effects. Please refer to full prescribing data in the SPC or the BNF

**Approval Date: 10/2020 Review Date: 10/2023** 2





## **Private and Confidential**

Specialist Prescriber

## **Apomorphine - Shared Care Request/Confirmation**

- Specialist Prescriber to complete first section of form and send to patient's GP.
- GP to complete second section of form and return to specialist prescriber within 28 days
- A copy of the full shared care guideline can be viewed at www.northoftyneapc.nhs.uk

•										
Departme	ent									
Hospital										
Telephon	e									
Patient de	etails (use hosp	oital label if pref	ferred)							
Name										
Address										
Postcode										
NHS or H	osp reg no		Male / Female DoB							
		<u> </u>	L .							
Treatment Requested for Prescribing in Accordance with an Approved Shared Care Arrangement										
Drug Info	rmation - Apor	norphine								
Formulat	ion			Dose			Frequency	/		
Indication – For the Management of Advanced Parkinson's Disease.										
Other information (if appropriate)										
	Specialist			Name				Date		
Prescribe	er)			(Print	)					
To be con	mnleted by GP						Ple	ase tick	cone hox	
To be completed by GP Please tick one box I ACCEPT the proposed shared care arrangement for this patient									CONO DOX	
I ACCEPT the proposed shared care arrangement with the caveats below										
I DO NOT ACCEPT the proposed shared care arrangement for this patient										
My caveats/reason(s) for not accepting include:										
Signed			Name (print	)			Dat	е		

N.B. Participation in this shared care arrangement implies that prescribing responsibility is shared between the specialist prescriber and the patient's GP

**Approval Date:** 10/2020 Review Date: 10/2023 3